- Home
- PLUR vs ENLV Comparison
PLUR vs ENLV Comparison
Compare PLUR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | ENLV |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 26.6M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | PLUR | ENLV |
|---|---|---|
| Price | $3.03 | $1.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $13.00 |
| AVG Volume (30 Days) | 20.6K | ★ 461.1K |
| Earning Date | 02-10-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,326,000.00 | N/A |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 121.74 | N/A |
| 52 Week Low | $2.82 | $0.66 |
| 52 Week High | $7.13 | $2.10 |
Technical Indicators
Market Signals| Indicator | PLUR | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 59.38 |
| Support Level | $3.01 | $0.85 |
| Resistance Level | $3.21 | $1.03 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 33.15 | 86.95 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.